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Abstract
Background: Whether cancer is more disabling than other highly prevalent chronic diseases in the
elderly is not well understood, and represents the objective of the present study.
Methods: We used data from the Gruppo Italiano di Farmacovigilanza nell'Anziano (GIFA) study, a large
collaborative observational study based in community and university hospitals located throughout Italy.
Our series consisted of three groups of patients with non-neoplastic chronic disease (congestive heart
failure, CHF, N = 832; diabetes mellitus, N = 939; chronic obstructive pulmonary disease, COPD, N =
399), and three groups of patients with cancer (solid tumors without metastasis, N = 813; solid tumors
with metastasis, N = 259; leukemia/lymphoma, N = 326). Functional capabilities were ascertained using the
activities of daily living (ADL) scale, and categorical variables for dependency in at least 1 ADL or
dependency in 3 or more ADLs were considered in the analysis. Cognitive status was evaluated by the 10-
items Hodgkinson Abbreviated Mental Test (AMT).
Results: Cognitive impairment was more prevalent in patients with CHF (28.0%) or COPD (25.8%) than
in those with cancer (solid tumors = 22.9%; leukemia/lymphoma = 19.6%; metastatic cancer = 22.8%).
Dependency in at least 1 ADL was highly prevalent in patients with metastatic cancer (31.3% vs. 24% for
patients with CHF and 22.4% for those with non-metastatic solid tumors, p < 0.001). In people aged 80
years or more, metastatic cancer was not associated with increased prevalence of physical disability. In
multivariable analysis, metastatic cancer was associated with a greater prevalence of physical (OR 2.09,
95%CI 1.51–2.90) but not cognitive impairment (OR 1.34, 95%CI 0.94–1.91) with respect to CHF patients.
Finally, diabetes was significantly associated with cognitive impairment (OR 1.40, 95%CI 1.11–1.78).
Conclusion: Cancer should not be considered as an ineluctable cause of severe cognitive and physical
impairment, at least not more than other chronic conditions highly prevalent in older people, such as CHF
and diabetes mellitus.
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Acute disabling conditions such as stroke or hip fracture
have obvious and dramatic effects on functional capabili-
ties, whereas chronic conditions which do not cause a seg-
mental motor deficit have a more complex and less
predictable effect. Clinical observations suggest that
chronic diseases may be associated with different patterns
of physical decline. For example, a distinctive pattern of
disability has been found in chronic obstructive pulmo-
nary disease (COPD) compared with that characterizing
patients with congestive heart failure (CHF) or diabetes
mellitus [1].
Physical dependency can be seen as the end result of the
complex interaction among physical, cognitive and affec-
tive factors. Cancer is commonly perceived as a highly dis-
abling condition, whereas the impact of other chronic
conditions such as diabetes mellitus or hypoxemic COPD
on functional capabilities is underestimated [2,3].
Given et al reported that, at the time of the first diagnosis,
older cancer patients have considerably better physical
function than persons of the same age from the general
population [4]. Thus, cancer, on average, might not be
more disabling than other highly prevalent chronic dis-
eases in the elderly. Clarifying this issue might be relevant
to quantify the needs of care besides the expenditure
directly related to the treatment of cancer as well as to
select patients most likely to benefit from a comprehen-
sive assessment program. [5]. Indeed, interventions
guided by geriatric assessment have positive effects on a
number of important health outcomes in frail older
patients in different settings [6-9]. However, older cancer
patients are underrepresented in geriatric assessment and
intervention trials [10]. This makes desirable to clarify the
impact of cancer on physical and mental capabilities in
comparison with that of conditions such as CHF, COPD
and diabetes mellitus which were highly prevalent in ger-
iatric series proven to benefit form geriatric assessment [6-
9]. This is the objective of the present study.
Methods
We used data from the Gruppo Italiano di Farmacovigi-
lanza nell'Anziano (GIFA) study, a large collaborative
observational study that periodically surveys drug con-
sumption, occurrence of adverse drug reactions (ADR),
and quality of hospital care. We used data on patients con-
secutively admitted to the participating centers during the
4 months surveys carried out in 1993, 1995, 1997 and
1998. Methods of the GIFA have been previously
described [11]. Briefly, after obtaining a written informed
consent, all patients admitted to the 81 participating
wards of Geriatric or Internal Medicine in tertiary hospi-
tals located throughout Italy were enrolled and followed
until discharge. There were no inclusion or exclusion cri-
teria. The majority of patients were admitted from the
Emergency Room at each hospital, and the diagnosis
made by the on-call physician in the Emergency Room
was recorded. For each patient a questionnaire was com-
pleted at admission and updated daily by a study physi-
cian who received specific training for the study.
Data recorded included demographic characteristics,
drugs taken prior to admission and during hospital stay,
and those prescribed at discharge, ADR, routine blood
examination tests, cognitive function, admission and dis-
charge diagnoses. All data were recorded at the clinical
center on a microcomputer by means of a dedicated soft-
ware. Such a software controlled the suitability and the
internal consistency of the data so that impossible values
or contradictory information could not be entered. The
software allowed automatic coding of diagnoses, of ADRs
and of drugs by simple typing the description of the dis-
ease, of the ADR, or of the commercial name of the drug.
Procedures conformed to guidelines provided by the
Catholic University Ethical Committee.
Overall, 17,186 patients were enrolled in the study
period. Patients who died during hospital stay were
excluded from the analysis to avoid the bias due to the
presence of terminal illness. We selected five groups of
patients on the basis of their first-listed diagnosis using
the International Classification of Diseases 9th revision
Clinical Modification (ICD9-CM) codes [12]. Three
groups consisted of patients with non-neoplastic chronic
disease (congestive heart failure, N = 832; diabetes melli-
tus, N = 939; chronic obstructive pulmonary disease, N =
399), and were compared to three groups of patients with
cancer: solid tumors (gastrointestinal, lung, breast, pros-
tate, oro-pharyngeal, bone, and genito-urinary cancer)
without metastasis (N = 813); solid tumors with metasta-
sis (N = 259); leukemia/lymphoma (N = 326)
Variables specifically considered in this study were age,
gender, length of hospital stay, number of diagnoses, use
of drugs and prevalence of adverse drug reactions during
hospital stay, and number of hospitalization in the last
year. Functional capabilities were ascertained using the
ADL scale [13], and categorical variables for dependency
in at least 1 ADL or dependency in 3 or more ADLs were
considered in the analysis. Cognitive status was evaluated
by the Hodgkinson Abbreviated Mental Test (AMT), that
is a 10-item version of the Blessed-Roth information-
memory-concentration test [14,15], validated in an Ital-
ian population for screening for dementia [16]. Each
question scores 1 point, and the total score ranges from 0
(no correct answer) to 10 (correct answers). On the week-
day after admission, the study physician identified
patients to be included in the study and interviewed them
on the day before discharge to avoid any interferencePage 2 of 8
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errors) has been reported to have 100% sensitivity and
71% specificity with respect to the DSM III diagnostic cri-
teria of dementia [16].
We used contingency tables to compare the demographic
and clinical characteristics of the groups studied. AMT and
ADL scores of patients with lung or gastrointestinal can-
cer, i.e. of the most frequent cancers in the population
studied, were separately analyzed to estimate the effects of
metastases on the functional capabilities in homogeneous
groups of cancer patients. Logistic regression analysis was
used to obtain a deconfounded estimate of the association
between the type of disease and physical or cognitive
impairment. All analyses were performed using SPSS
V10.0 (SPSS Inc., Chicago IL)[17].
Results
The prevalence of patients aged 80 or more was higher in
CHF and COPD than in diabetes and cancer groups, while
male gender was more frequent in patients with COPD
and cancer. Comorbidity was greater in diabetic patients,
while patients with leukemia/lymphoma or metastatic
cancer had the longest average stay. Use of NSAIDs and
analgesics was greater in patients with diabetes and can-
cer, particularly in those with metastases. The highest rate
of hospitalization in the previous year was observed in
patients with COPD and cancer (Table 1).
Patients with cancer had a lower prevalence of cognitive
impairment (22.9% in patients with solid tumors; 19.6%
in patients with leukemia/lymphoma; 22.8% in patients
with metastatic cancer) compared to patients with CHF
(28.0%) or COPD (25.8%). Physical dependency was
highly prevalent in patients with metastatic cancer
(dependent in at least 1 ADL, 31.3%; dependent in 3 or
more ADLs, 27.4%). The corresponding figures for
patients with CHF were 24.0% and 19.6%, respectively
(Figure 1, panel A).
Physical dependency in at least 1 ADL was significantly
associated with higher comorbidity in patients with CHF
(p < 0.05), diabetes (p < 0.01) or metastatic cancer (p <
0.05), but not in those with COPD, non-metastatic solid
tumors or leukemia/lymphoma (figure 1, panel B). No
significant association between cognitive performance
and comorbidity was observed (data not shown).
For patients with gastrointestinal cancer (figure 1, panel
C) and lung cancer (figure 1, panel D), the presence of
metastases was associated to a slight increase in the prev-
alence of physical dysfunction, and to a slight decrease in
the prevalence of cognitive impairment. However, these
differences were not statistically significant.
When we repeated the analysis in people aged 80 years or
more (figure 2), we found that the prevalence of cognitive
dysfunction was similar in all the conditions considered,
including metastatic cancer. Furthermore, the prevalence
of physical disability did not distinguish metastatic cancer
from the remaining conditions.
The gender-specific limitations of functional capabilities
are reported in figure 3. The highest prevalence of cogni-
tive impairment was observed in males with CHF (23.0%)
or COPD (24.6%) and in females with CHF (32.3%) or
metastatic cancer (32.0%). Metastatic cancer was associ-
ated with the highest prevalence of physical dependency

















<65 8.4 29.9 16.3 20.9 27.3 30.1
65–79 45.2 45.8 44.6 46.4 46.0 41.7
80+ 46.3 24.3 39.1 32.7 26.7 28.2
Gender (males) 46.0 45.2 63.2 67.7 51.2 61.4 0.001
No of diagnoses>4 35.3 48.3 17.0 29.8 37.7 35.1 0.001
Length of stay>14 days 33.1 36.1 30.1 35.8 41.4 40.5 0.01
ADR during stay 12.1 10.4 6.3 7.4 7.7 10.4 0.002
Drugs during stay
NSAIDs 3.6 10.5 4.8 13.7 15.6 28.6 0.001
Analgesics 0.2 8.0 1.3 3.8 3.1 6.9 0.001
More than 2 hospitalization in the last year 9.4 8.7 12.0 12.2 19.0 15.1 0.001
CHF = congestive heart failure; COPD = chronic obstructive pulmonary disease; ADR = adverse drug reactions; NSAIDs = non-steroidal 
antinflammatory drugs.
Data are percentage. P values in the last column refer to the 6 groups for 2 levels chi-square test.Page 3 of 8
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divided patients according to the number of diseases, CHF
and COPD were associated with the greatest prevalence of
cognitive impairment (29.2% and 26.9%, respectively) in
patients with less than 5 diagnoses, while among patients
with more than 4 diagnoses, the greatest prevalence of
cognitive impairment was observed in CHF (25.9%) and
metastatic cancer (27.5%) groups. Metastatic cancer was
associated with the highest prevalence of physical
dependency regardless of comorbidity (Figure 3, panel C
and D).
Finally, after simultaneous adjustment for age, gender,
number of drugs, number of diagnoses, and length of stay,
only metastatic cancer was associated with a greater prev-
alence of physical but not cognitive impairment with
respect to CHF patients. Diabetes was significantly associ-
ated with cognitive impairment (Table 2).
Discussion
Our study indicates that physical performance and cogni-
tive status in patients with non-metastatic cancer did not
significantly differ from those observed in older hospital-
ized patients with other non-neoplastic chronic diseases.
In presence of metastases, however, physical dependency
Panel A: prevalence of cognitive impairment and physical disability in patients divided according to their main diagnosisFigure 1
Panel A: prevalence of cognitive impairment and physical disability in patients divided according to their main diagnosis. Panel B: 
association between physical disability (dependency in at least 1 ADL) and comorbidity in the groups studied. Panel C and D: 
prevalence of cognitive impairment and physical disability in patients with gastrointestinal or lung cancer, with or without 
metastases.Page 4 of 8
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nificantly more prevalent in CHF than in metastatic can-
cer patients. Furthermore, compared to patients with
CHF, those with metastatic cancer had longer hospital
stay, greater number of hospitalization in the last year,
and used more anti-inflammatory and analgesic drugs.
Thus, our data confirm the common perception of meta-
static cancer as a disease dramatically impacting on the
health status, but this view should take into account the
differential effect of cancer on physical and mental
domains. On the other hand, non-metastatic cancer does
not outweigh non-neoplastic chronic diseases as a cause
of physical and cognitive impairment. It is interesting to
note, however, that the presence of metastases had a dis-
tinctive impact on health status only in people aged less
than 80. This finding may be consistent either with selec-
tive survival up to older ages or with a real lack of differ-
ence in the effects on health status of non-malignant
chronic diseases (especially diabetes and CHF) and meta-
static cancer in the very old.
Assessing the health status is relevant to optimize the ther-
apy of cancer in the elderly. On average, the elderly are as
likely to benefit from standard cancer treatment as
younger people do [4]. Only older patients with func-
tional and cognitive impairment are at higher risk of
developing complications in response to aggressive treat-
ments [18]. Thus, there is no sound basis for the common
practice of treating the elderly with substandard therapy
because of the perceived minimal benefit of chemother-
apy and great risk of toxicity [18]. Age bias may affect both
physicians' attitudes toward the use of standard anticancer
therapeutic regimens in elderly patients [19], and the
recruitment of elderly cancer patients in clinical trials
[20,21]. Our data show that only one out of three older
patients with metastatic cancer has severely impaired
physical capabilities, whereas cognitive impairment is less
common. Thus, in an unselected elderly population most
of patients with metastatic cancer seem to be amenable to
standard oncologic therapy, at least on the basis of their
physical and cognitive capabilities.
Prevalence of cognitive impairment and physical disability in patients aged 80 years or more (N = 1196) grouped according to th ir main diagnosisFigur  2
Prevalence of cognitive impairment and physical disability in patients aged 80 years or more (N = 1196) grouped according to 
their main diagnosis.Page 5 of 8
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Prevalence of cognitive impairment and physical disability in: male patients divided according to their main diagnosis (Panel A); 
female patients divided according to their main diagnosis (Panel B); patients with less than 5 diagnoses divided according to 
their main diagnosis (Panel C); patients with more than 4 diagnoses divided according to their main diagnosis (Panel D).
Table 2: Summary logistic regression models* of main diagnosis to cognitive impairment or physical dependency in at least 1 ADL.
Cognitive impairment OR (95%CI) Dependency in at least 1 ADL OR (95%CI)
CHF 1.0 (reference) 1.0 (reference)
Diabetes 1.40 (1.11–1.78) 0.93 (0.73–1.19)
COPD 1.13 (0.85–1.51) 0.73 (0.53–1.10)
Solid tumors 1.09 (0.85–1.39) 1.23 (0.95–1.57)
Leukemia/lymphoma 0.99 (0.70–1.38) 1.05 (0.75–1.47)
Metastatic cancer 1.34 (0.94–1.91) 2.09 (1.51–2.90)
*After adjusting for age, gender, number of drugs, number of diagnoses, and length of stay.Page 6 of 8
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ing number of reports [22,23]. Our study adds to current
knowledge by showing that CHF approaches metastatic
cancer as a disabling condition, but, compared with met-
astatic cancer, it impacts more on mental than on physical
capabilities. Indeed, cognitive dysfunction is highly prev-
alent in CHF populations and represents an important
health problem, for example by affecting the compliance
with therapy [22]. These findings might help understand
the positive effects of geriatric assessment and interven-
tion trial in CHF [24,25]. Indeed, physical rehabilitation
and strategies enhancing the compliance with drugs and
life style measures were a primary component of such tri-
als [24]. Similarly, the association between diabetes and
cognitive impairment is well known [26]. Our findings
confirm this association and further stresses that
metastatic cancer does not primarily affect mental
performance.
Limitations of our study deserve to be cited. First, a cross-
sectional observation is exploratory in nature, and it
should be prospectively replicated. Furthermore, by con-
sidering only patients admitted to the acute care hospital,
our sample can not be considered fully representative of
the general population of older people. Second, the gen-
eral health status of patients admitted to Geriatric or Inter-
nal Medicine units may be different from those admitted
to Oncology or other specialty units. We excluded people
dying during the hospital stay to avoid the bias introduced
in the analysis by people with terminal illness. The GIFA
questionnaire, however, does not contain an item on
explicit terminal prognosis, therefore we could have
excluded people with more advanced, but not terminal,
disease. This could have biased our results by inflating the
proportion of people with less advanced cancer progres-
sion. Nonetheless, by excluding people who died regard-
less of the diagnosis, we also excluded people with more
advanced CHF or COPD, and this is likely to have offset
the potential bias. Third, the use of a single cognitive
screening test did not allow us to investigate the impact of
selected chronic conditions on specific cognitive
domains. Finally, comorbidity variously affects functional
capabilities and thus might be responsible for some of the
differences among groups. However, also in patients with
more than 4 diagnoses, only the presence of metastatic
cancer was associated with physical but not cognitive
impairment. Furthermore, comorbidity usually
characterizes patients having these main diseases, which
makes present findings representative of the clinical
reality.
Conclusion
Cancer should not be considered as an ineluctable cause
of severe cognitive and physical impairment, at least not
more than other chronic conditions highly prevalent in
older people, such as CHF. Further studies should be car-
ried out to explain in which measure the impairment of
mental and functional capabilities depends upon cancer
per se or cancer related pain or comorbid conditions. Clar-
ifying this issue in the individual patient would improve
interventions aimed at reducing the burden of cognitive
and physical dysfunction and improving health status in
older patients with cancer.
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